Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Australia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme

Optimi Health Corp. (CSE: OPTI,OTC:OPTHF) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme.

The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturally derived psilocybin capsules in a 5 mg dosage form. Final packaging, labelling, and batch release were completed in accordance with Optimi's Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/281580_66f04ec31421584a_001full.jpg

"This production run has been released and approved for import, allowing Optimi to continue supplying MDMA and psilocybin into Australia's regulated healthcare system," said Dane Stevens, Chief Executive Officer of Optimi Health. "Completing this first production cycle of 2026 positions us to expand access across the country for patients suffering from PTSD and TRD."

Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments.

Australian clinics, hospital networks, and programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org. For global inquiries outside of Australia, please contact the Company at sales@optimihealth.ca.

About Optimi Health Corp.

Optimi Health Corp. (CSE: OPTI,OTC:OPTHF) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281580